US5112868A
(en)
*
|
1988-05-19 |
1992-05-12 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
|
US4943587A
(en)
*
|
1988-05-19 |
1990-07-24 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
|
US5068251A
(en)
*
|
1988-12-16 |
1991-11-26 |
Abbott Laboratories |
Lipoxygenase inhibiting compounds
|
US5212189A
(en)
*
|
1991-12-17 |
1993-05-18 |
Warner-Lambert Company |
Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
|
US6410729B1
(en)
|
1996-12-05 |
2002-06-25 |
Amgen Inc. |
Substituted pyrimidine compounds and methods of use
|
US6096753A
(en)
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
US6107291A
(en)
*
|
1997-12-19 |
2000-08-22 |
Amgen Inc. |
Azepine or larger medium ring derivatives and methods of use
|
US6174901B1
(en)
|
1998-12-18 |
2001-01-16 |
Amgen Inc. |
Substituted pyridine and pyridazine compounds and methods of use
|
US6335329B1
(en)
|
1997-12-19 |
2002-01-01 |
Amgen Inc. |
Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
US6429223B1
(en)
*
|
2000-06-23 |
2002-08-06 |
Medinox, Inc. |
Modified forms of pharmacologically active agents and uses therefor
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
ATE493987T1
(de)
|
2002-05-22 |
2011-01-15 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
US6908935B2
(en)
|
2002-05-23 |
2005-06-21 |
Amgen Inc. |
Calcium receptor modulating agents
|
US7176322B2
(en)
|
2002-05-23 |
2007-02-13 |
Amgen Inc. |
Calcium receptor modulating agents
|
AR041191A1
(es)
|
2002-08-08 |
2005-05-04 |
Amgen Inc |
Ligandos del receptor vanilloide y su uso en tratamientos
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7442698B2
(en)
|
2003-07-24 |
2008-10-28 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7582631B2
(en)
|
2004-01-14 |
2009-09-01 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7429616B2
(en)
|
2005-07-15 |
2008-09-30 |
Board Of Regents, University Of Texas System |
Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
|
US7754717B2
(en)
|
2005-08-15 |
2010-07-13 |
Amgen Inc. |
Bis-aryl amide compounds and methods of use
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
WO2007117981A2
(en)
|
2006-03-29 |
2007-10-18 |
Novartis Ag |
Selective hydroxamate based mmp inhibitors
|
CA2787343C
(en)
|
2006-06-26 |
2016-08-02 |
Amgen Inc. |
Compositions comprising modified lcat and uses thereof
|
CA2656535C
(en)
|
2006-07-14 |
2011-08-23 |
Amgen Inc. |
Alkyne-substituted pyridone compounds and methods of use
|
JP5042311B2
(ja)
|
2006-07-20 |
2012-10-03 |
ノバルティス アーゲー |
Cetp阻害剤としてのアミノピペリジン誘導体
|
EP2079724B1
(en)
|
2006-07-20 |
2010-05-26 |
Amgen Inc. |
Substituted pyridone compounds and methods of use
|
WO2008011110A2
(en)
|
2006-07-20 |
2008-01-24 |
Amgen Inc. |
Di-amino-substituted heterocyclic compounds and methods of use
|
EP2137186B1
(en)
|
2007-03-23 |
2016-01-27 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
EP2463282B1
(en)
|
2007-11-05 |
2013-08-07 |
Novartis AG |
4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
|
CA2707651A1
(en)
|
2007-12-03 |
2009-06-11 |
Novartis Ag |
1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
|
KR101673621B1
(ko)
|
2008-03-24 |
2016-11-07 |
노파르티스 아게 |
아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
|
ES2397934T3
(es)
|
2008-12-17 |
2013-03-12 |
Amgen Inc. |
Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
|
WO2010075869A1
(en)
|
2008-12-30 |
2010-07-08 |
European Molecular Biology Laboratory (Embl) |
Toluidine sulfonamides and their use
|
WO2010085968A1
(en)
|
2008-12-30 |
2010-08-05 |
European Molecular Biology Laboratory (Embl) |
Toluidine sulfonamides and their use as hif-inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
MX2011012198A
(es)
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Aril-piridinas como inhibidoras de sintasa de aldosterona.
|
AU2010251967B9
(en)
|
2009-05-28 |
2014-04-03 |
Novartis Ag |
Substituted aminopropionic derivatives as neprilysin inhibitors
|
MX2011012627A
(es)
|
2009-05-28 |
2011-12-14 |
Novartis Ag |
Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
|
MX2011013666A
(es)
|
2009-06-25 |
2012-03-06 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
US8765940B2
(en)
|
2009-06-25 |
2014-07-01 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
AR077267A1
(es)
|
2009-06-25 |
2011-08-17 |
Amgen Inc |
Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
|
AU2010266064A1
(en)
|
2009-06-25 |
2012-01-19 |
Amgen Inc. |
4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors
|
AR077328A1
(es)
|
2009-07-24 |
2011-08-17 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
|
EP2470502A1
(en)
|
2009-08-26 |
2012-07-04 |
Novartis AG |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
NZ598781A
(en)
|
2009-09-03 |
2014-05-30 |
Allergan Inc |
Compounds as tyrosine kinase modulators
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
AU2010291199A1
(en)
|
2009-09-04 |
2012-03-08 |
Novartis Ag |
Pyrazinylpyridines useful for the treatment of proliferative diseases
|
MX2012002752A
(es)
|
2009-09-04 |
2012-04-19 |
Novartis Ag |
Compuestos de heteroarilo como inhibidores de cinasa.
|
US20110130380A1
(en)
|
2009-09-04 |
2011-06-02 |
Barsanti Paul A |
Heteroaryl Kinase Inhibitors
|
AR078770A1
(es)
|
2009-10-27 |
2011-11-30 |
Elara Pharmaceuticals Gmbh |
Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
|
WO2011061168A1
(en)
|
2009-11-17 |
2011-05-26 |
Novartis Ag |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(en)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazole derivatives as aldosterone synthase inhibitors
|
US8633313B2
(en)
|
2009-12-18 |
2014-01-21 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
WO2011073316A1
(en)
|
2009-12-18 |
2011-06-23 |
Novartis Ag |
4-aryl-butane-1,3-diamides
|
EP2516437B1
(en)
|
2009-12-21 |
2014-01-29 |
Novartis AG |
Disubstituted heteroaryl-fused pyridines
|
EP2516439B1
(en)
|
2009-12-21 |
2014-01-22 |
Novartis AG |
Diaza-spiro[5.5]undecanes as orexin receptor antagonists
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
AR080055A1
(es)
|
2010-02-01 |
2012-03-07 |
Novartis Ag |
Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
|
AR080056A1
(es)
|
2010-02-01 |
2012-03-07 |
Novartis Ag |
Derivados de ciclohexil-amida como antagonistas de los receptores de crf
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
US8835444B2
(en)
|
2010-02-02 |
2014-09-16 |
Novartis Ag |
Cyclohexyl amide derivatives as CRF receptor antagonists
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
AR082453A1
(es)
|
2010-04-21 |
2012-12-12 |
Novartis Ag |
Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
|
MX2012013127A
(es)
|
2010-05-13 |
2012-11-30 |
Amgen Inc |
Compuestos heteroariloxiheterociclilo como inhibidores pde10.
|
BR112012029026A2
(pt)
|
2010-05-13 |
2016-08-02 |
Amgen Inc |
composto heretocíclicos de nitrogênio úteis como inbidores pde10
|
AU2011253143A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
|
CA2799020A1
(en)
|
2010-05-13 |
2011-11-17 |
Jennifer R. Allen |
Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
|
EP2582680A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
UY33469A
(es)
|
2010-06-29 |
2012-01-31 |
Irm Llc Y Novartis Ag |
Composiciones y metodos para modular la via de señalizacion de wnt
|
CA2803619A1
(en)
|
2010-06-30 |
2012-01-05 |
Amgen Inc. |
Heterocycle compounds and their uses
|
EP2588473A1
(en)
|
2010-06-30 |
2013-05-08 |
Amgen Inc. |
Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
|
MX2012015147A
(es)
|
2010-06-30 |
2013-05-01 |
Amgen Inc |
Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
|
WO2012003262A1
(en)
|
2010-07-01 |
2012-01-05 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of pi3k activity
|
EP2588467A1
(en)
|
2010-07-01 |
2013-05-08 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of pi3k activity
|
EP2588469A1
(en)
|
2010-07-02 |
2013-05-08 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of pi3k activity
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
PL2483255T3
(pl)
|
2010-07-13 |
2014-03-31 |
Novartis Ag |
Pochodne oksazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych
|
EA022046B1
(ru)
|
2010-07-14 |
2015-10-30 |
Новартис Аг |
Гетероциклические соединения, агонисты рецептора ip
|
CN103025728B
(zh)
|
2010-07-22 |
2015-11-25 |
诺华股份有限公司 |
2,3,5-三取代的噻吩化合物及其用途
|
US9290485B2
(en)
|
2010-08-04 |
2016-03-22 |
Novartis Ag |
N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
|
SG188438A1
(en)
|
2010-09-13 |
2013-05-31 |
Novartis Ag |
Triazine-oxadiazoles
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
CN103313988B
(zh)
|
2010-09-20 |
2016-06-08 |
论坛医药有限公司 |
咪唑并三嗪酮化合物
|
US20120101110A1
(en)
|
2010-10-26 |
2012-04-26 |
Sangamesh Badiger |
Diaza-spiro[5.5]undecanes
|
US20140031355A1
(en)
|
2010-11-04 |
2014-01-30 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
JP2013543000A
(ja)
|
2010-11-17 |
2013-11-28 |
アムジエン・インコーポレーテツド |
複素環化合物およびその使用
|
JP2014500277A
(ja)
|
2010-12-09 |
2014-01-09 |
アムジエン・インコーポレーテツド |
Pim阻害剤としての二環式化合物
|
EP2655369A1
(en)
|
2010-12-20 |
2013-10-30 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
CN103370315A
(zh)
|
2010-12-20 |
2013-10-23 |
Irm责任有限公司 |
用于调控法尼醇x受体的组合物和方法
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
MX2013007261A
(es)
|
2010-12-23 |
2013-11-04 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
ES2647664T3
(es)
|
2011-01-04 |
2017-12-26 |
Novartis Ag |
Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD)
|
JP2014505689A
(ja)
|
2011-01-13 |
2014-03-06 |
ノバルティス アーゲー |
代謝障害の処置用bace−2阻害剤
|
WO2012101063A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyridine biaryl compounds and their uses
|
WO2012101066A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyridine biaryl amine compounds and their uses
|
WO2012101064A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
|
WO2012101065A2
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyrimidine biaryl amine compounds and their uses
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
JP2014510105A
(ja)
|
2011-03-22 |
2014-04-24 |
アムジエン・インコーポレーテツド |
Pim阻害剤としてのアゾール化合物
|
WO2012130306A1
(en)
|
2011-03-30 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
|
WO2012130314A1
(en)
|
2011-03-31 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Composition comprising docetaxel
|
WO2012130322A1
(en)
|
2011-03-31 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Imidazo [1,2-a]pyridine compounds for use in therapy
|
WO2012138648A1
(en)
|
2011-04-06 |
2012-10-11 |
Irm Llc |
Compositions and methods for modulating lpa receptors
|
EP2702063A1
(en)
|
2011-04-29 |
2014-03-05 |
Amgen Inc. |
Bicyclic pyridazine compounds as pim inhibitors
|
AU2012272898A1
(en)
|
2011-06-24 |
2013-04-11 |
Amgen Inc. |
TRPM8 antagonists and their use in treatments
|
EA201490152A1
(ru)
|
2011-06-24 |
2014-05-30 |
Эмджен Инк. |
Антагонисты trpm8 и их применение при лечении
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
JP2014530851A
(ja)
|
2011-10-21 |
2014-11-20 |
ノバルティスアーゲー |
Pi3kモジュレータとしてのキナゾリン誘導体
|
EP2802582A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
US20140378463A1
(en)
|
2012-01-13 |
2014-12-25 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
US9115129B2
(en)
|
2012-01-13 |
2015-08-25 |
Novartis Ag |
Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
|
US20150005311A1
(en)
|
2012-01-13 |
2015-01-01 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
US8937069B2
(en)
|
2012-01-13 |
2015-01-20 |
Novartis Ag |
Substituted pyrrolo[2,3-B]pyrazine compounds and their use
|
US9394297B2
(en)
|
2012-02-28 |
2016-07-19 |
Amgen Inc. |
Amides as pim inhibitors
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
EP2828262A4
(en)
|
2012-03-19 |
2015-09-23 |
Forum Pharmaceuticals Inc |
IMIDAZOTRIAZINONVERBINDUNGEN
|
ES2577109T3
(es)
|
2012-04-04 |
2016-07-13 |
Amgen Inc. |
Compuestos heterocíclicos y sus usos
|
MX2014013428A
(es)
|
2012-05-04 |
2015-02-04 |
Novartis Ag |
Moduladores de la ruta del complemento y usos de los mismos.
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
WO2013184766A1
(en)
|
2012-06-06 |
2013-12-12 |
Irm Llc |
Compounds and compositions for modulating egfr activity
|
UY34858A
(es)
|
2012-06-14 |
2013-11-29 |
Amgen Inc |
Compuestos de azetidina y piperidina útiles como inhibidores de pde10
|
CA2877526A1
(en)
|
2012-06-20 |
2013-12-27 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
WO2014002053A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
US9464081B2
(en)
|
2012-06-28 |
2016-10-11 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
MX2014015738A
(es)
|
2012-06-28 |
2015-08-06 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
|
JP6273274B2
(ja)
|
2012-06-28 |
2018-01-31 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
EP2867227B1
(en)
|
2012-06-28 |
2018-11-21 |
Novartis AG |
Complement pathway modulators and uses thereof
|
CN104619698B
(zh)
|
2012-06-28 |
2016-08-31 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
BR112015000578A2
(pt)
|
2012-07-12 |
2017-06-27 |
Novartis Ag |
moduladores da via do complemento e usos dos mesmos
|
WO2014022752A1
(en)
|
2012-08-03 |
2014-02-06 |
Amgen Inc. |
Macrocycles as pim inhibitors
|
WO2014023329A1
(en)
|
2012-08-06 |
2014-02-13 |
Life And Brain Gmbh |
Niclosamide and its derivatives for use in the treatment of solid tumors
|
WO2014041125A1
(en)
|
2012-09-13 |
2014-03-20 |
Baden-Württemberg Stiftung Gmbh |
Specific inhibitors of protein p21 as therapeutic agents
|
CN105189500A
(zh)
|
2013-02-13 |
2015-12-23 |
诺华股份有限公司 |
Ip受体激动剂杂环化合物
|
CU24330B1
(es)
|
2013-02-14 |
2018-03-13 |
Novartis Ag |
Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
EP2924026A1
(en)
|
2014-03-28 |
2015-09-30 |
Novartis Tiergesundheit AG |
Aminosulfonylmethylcyclohexanes as JAK inhibitors
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
CN107531686B
(zh)
|
2015-03-24 |
2021-07-09 |
亥姆霍兹感染研究中心有限责任公司 |
铜绿假单胞菌LecB的抑制剂
|
WO2016174616A1
(en)
|
2015-04-30 |
2016-11-03 |
Novartis Ag |
Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
|
AU2016308568A1
(en)
|
2015-08-19 |
2018-02-22 |
Vivus Llc |
Pharmaceutical formulations
|
CN105418480B
(zh)
*
|
2015-11-16 |
2019-05-10 |
青岛大学 |
2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
|
MX2018007432A
(es)
|
2015-12-18 |
2018-09-21 |
Amgen Inc |
Compuestos de dihidroquinolinsulfonamida de alquilo.
|
CA3008485C
(en)
|
2015-12-18 |
2023-08-01 |
Amgen Inc. |
Alkynyl dihydroquinoline sulfonamide compounds
|
WO2018146612A1
(en)
|
2017-02-10 |
2018-08-16 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
|
EP3638662A1
(en)
|
2017-06-14 |
2020-04-22 |
European Molecular Biology Laboratory |
Benzofuran ureas or carbamates and heteroaromatic analogues thereof for use in therapy
|
EP3638667A1
(en)
|
2017-06-14 |
2020-04-22 |
European Molecular Biology Laboratory |
Bicyclic heteroaromatic amide compounds for use in therapy
|
EP3638668A1
(en)
|
2017-06-14 |
2020-04-22 |
European Molecular Biology Laboratory |
Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
|
WO2018229193A1
(en)
|
2017-06-14 |
2018-12-20 |
European Molecular Biology Laboratory |
Benzofuran amides and heteroaromatic analogues thereof for use in therapy
|
WO2019154859A1
(en)
|
2018-02-06 |
2019-08-15 |
Universität Heidelberg |
Fap inhibitor
|
WO2019154886A1
(en)
|
2018-02-06 |
2019-08-15 |
Universität Heidelberg |
Fap inhibitor
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201811825D0
(en)
|
2018-07-19 |
2018-09-05 |
Benevolentai Bio Ltd |
Organic compounds
|
GB201813791D0
(en)
|
2018-08-23 |
2018-10-10 |
Benevolental Bio Ltd |
Organic compounds
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
TW202034924A
(zh)
|
2018-12-20 |
2020-10-01 |
美商安進公司 |
Kif18a 抑制劑
|
MX2021007158A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001295A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
CA3159906A1
(en)
|
2019-11-05 |
2021-05-14 |
Helmholtz-Zentrum Fur Infektionsforschung Gmbh |
Bivalent leca inhibitors targeting biofilm formation of pseudomonas aeruginosa
|
BR112022013156A2
(pt)
|
2020-01-22 |
2022-10-18 |
Benevolentai Bio Ltd |
Composições farmacêuticas e seus usos
|
CA3163581A1
(en)
|
2020-01-22 |
2021-07-29 |
Benevolentai Bio Limited |
Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
|
TW202203919A
(zh)
|
2020-04-14 |
2022-02-01 |
美商安進公司 |
用於治療贅生性疾病之kif18a抑制劑
|
WO2021234181A1
(en)
|
2020-05-22 |
2021-11-25 |
Universität Heidelberg |
Use of fap inhibitor in a method of diagnosis
|
JP2021195367A
(ja)
|
2020-06-10 |
2021-12-27 |
アムジエン・インコーポレーテツド |
シクロプロピルジヒドロキノリンスルホンアミド化合物
|
JP2021195368A
(ja)
|
2020-06-10 |
2021-12-27 |
アムジエン・インコーポレーテツド |
シクロブチルジヒドロキノリンスルホンアミド化合物
|
US20240025849A1
(en)
|
2020-08-26 |
2024-01-25 |
Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Inhibitors of no production
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Alc1抑制劑及與parpi之協同性
|
AU2021401426A1
(en)
|
2020-12-17 |
2023-06-22 |
Trustees Of Tufts College |
Fap-activated radiotheranostics, and uses related thereto
|
TW202325276A
(zh)
|
2021-10-29 |
2023-07-01 |
德商艾斯巴赫生物有限公司 |
結合至新穎異位結合位之病毒解旋酶抑制劑
|
TW202348228A
(zh)
|
2022-02-24 |
2023-12-16 |
德商艾斯巴赫生物有限公司 |
病毒組合療法
|
WO2023213833A1
(en)
|
2022-05-02 |
2023-11-09 |
Eisbach Bio Gmbh |
Use of alc1 inhibitors and synergy with parpi
|
WO2024022332A1
(en)
|
2022-07-26 |
2024-02-01 |
Shanghai Sinotau Biotech. Co., Ltd |
Fap inhibitors
|